Cabaletta Bio (CABA) Capital Leases (2024 - 2025)
Cabaletta Bio's (CABA) quarterly Capital Leases came in at $2.9 million in Q4 2025, down 11.17% year-on-year from $3.2 million in Q4 2024, and down 36.84% quarter-over-quarter from $4.6 million in Q3 2025.
Cabaletta Bio (CABA) Capital Leases (2024 - 2025) Analysis & Trends
Cabaletta Bio's Capital Leases history runs 2 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- On a quarterly basis, Capital Leases fell 11.17% year-over-year to $2.9 million in Q4 2025; TTM through Dec 2025 was $2.9 million, a 11.17% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 11.17% from the prior year.
- Capital Leases slipped to $2.9 million in Q4 2025 per CABA's latest filing, from $4.6 million in the prior quarter.
- Across five years, Capital Leases topped out at $8.1 million in Q1 2025 and bottomed at $2.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cabaletta Bio | 182.04 Mn | 182.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.88 Mn |
| Sep 30, 2025 | 4.56 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 8.11 Mn |
| Dec 31, 2024 | 3.24 Mn |